Back
Blueprint Medicines Stock Price Chart

7 Stocks to Consider Immediately (must-see chart)
See the green days for 7 major stocks right here, free of charge
Sell
48
BPMC
Blueprint Medicines
Last Price:
$128.68
Seasonality Move:
7.99%
7 Day Trial
ALL ACCESS PASS
$
7

ALERT: Q3 Could Be a Pivotal Quarter for Nasdaq Stocks
Click Here to Download Your FREE Stock Report Now-
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BPMC is experiencing buying pressure, which is a positive indicator for future bullish movement.
Blueprint Medicines Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 128.25 | Buy |
20-day SMA: | 128.17 | Buy |
50-day SMA: | 112.43 | Buy |
200-day SMA: | 97.81 | Buy |
8-day EMA: | 128.21 | Buy |
20-day EMA: | 125.53 | Buy |
50-day EMA: | 115.59 | Buy |
200-day EMA: | 101.04 | Buy |
Blueprint Medicines Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 4.37 | Buy |
Relative Strength Index (14 RSI): | 74.7 | Buy |
Chaikin Money Flow: | 1263634 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (121.79 - 132.29) | Buy |
Bollinger Bands (100): | (84.54 - 117.4) | Buy |
Blueprint Medicines Technical Analysis
Jun 23 | Jun 24 | Jun 25 | Jun 26 | Jun 27 | Jun 30 | Jul 1 | Jul 2 | Jul 3 | Jul 7 | |
---|---|---|---|---|---|---|---|---|---|---|
Jun | Jul | |||||||||
23 | 24 | 25 | 26 | 27 | 30 | 01 | 02 | 03 | 07 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Blueprint Medicines Stock
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 128.40 while BPMC 8-day simple moving average is 128.25, which is a Buy signal.
-
The stock price of BPMC is 128.40 while Blueprint Medicines 20-day SMA is 128.17, which makes it a Buy.
-
Blueprint Medicines 50-day simple moving average is 112.43 while BPMC share price is 128.40, making it a Buy technically.
-
BPMC stock price is 128.40 and Blueprint Medicines 200-day simple moving average is 97.81, creating a Buy signal.
BPMC Technical Analysis vs Fundamental Analysis
Sell
48
Blueprint Medicines (BPMC)
is a Sell
Is Blueprint Medicines a Buy or a Sell?
-
Blueprint Medicines stock is rated a SellThe current Blueprint Medicines [BPMC] share price is $128.40. The Score for BPMC is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
Blueprint Medicines Stock Info
Market Cap:
8.3B
Price in USD:
128.40
Share Volume:
1.9M
Blueprint Medicines 52-Week Range
52-Week High:
128.52
52-Week Low:
73.04
Sell
48
Blueprint Medicines (BPMC)
is a Sell
Blueprint Medicines Share Price Forecast
-
What is the Blueprint Medicines stock price today?The Blueprint Medicines stock price is 128.40 USD today.
-
Will BPMC stock go up or go down?Blueprint Medicines> share price is forecast to RISE/FALL based on technical indicators
-
Is Blueprint Medicines overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Blueprint Medicines is overvalued.
Is Blueprint Medicines Stock a Buy?
-
Blueprint Medicines share price is 128.40 while BPMC 8-day exponential moving average is 128.21, which is a Buy signal.
-
The stock price of BPMC is 128.40 while Blueprint Medicines 20-day EMA is 125.53, which makes it a Buy.
-
Blueprint Medicines 50-day exponential moving average is 115.59 while BPMC share price is 128.40, making it a Buy technically.
-
BPMC stock price is 128.40 and Blueprint Medicines 200-day simple moving average is 101.04, creating a Buy signal.
Fundamental Analysis of Blueprint Medicines
Is Blueprint Medicines a good investment?
-
Analysts estimate an earnings increase this quarter of $0.67 per share, an increase next quarter of $0.33 per share, an increase this year of $0.60 per share, and an increase next year of $1.50 per share.
Technical Analysis of Blueprint Medicines
Should I short Blueprint Medicines stock?
-
BPMC Moving Average Covergence Divergence (MACD) indicator is 4.37, suggesting Blueprint Medicines is a Buy
-
Blueprint Medicines Relative Strength Index (RSI) is 74.7, which suggest Blueprint Medicines is overbought
-
The Bollinger Bands (25) for Blueprint Medicines is (121.79 - 132.29), which suggest Blueprint Medicines is a Buy
-
The Bollinger Bands (100) for Blueprint Medicines is (84.54 - 117.4), which suggest Blueprint Medicines is a Buy
* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.